AGL

agilon health inc

Add to Watchlist

Advanced Chart

2.970

+0.080(+2.770%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

3.050

Open

2.950

VWAP

2.96

Vol

4.12M

Mkt Cap

1.23B

Low

2.860

Amount

12.19M

EV/EBITDA(TTM)

Total Shares

411.26M

864.16M

EV/OCF(TTM)

P/S(TTM)

0.20

agilon health, inc. is a healthcare company. It enables primary care physicians (PCP) to be the agents for change in the communities they serve. Through its combination of the agilon platform, a long-term partnership model with existing physician groups and a growing network of like-minded physicians, it offers healthcare for seniors across communities throughout the United States. Its model operates by primarily forming risk-bearing entities (RBEs) within local geographies, that enter into arrangements with payors providing for monthly payments to manage the total healthcare needs of its physician partners’ attributed patients (or global capitation arrangements). It focuses on community-based physician groups and is built around three key elements: agilon’s platform, agilon’s long-term physician partnership approach, and agilon’s network. The agilon platform is holistic in supporting the rapid transition to a Total Care Model with technology, people, process and capital.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

1.57B

+5.83%

0.001

-100.87%

1.50B

+3.54%

-0.040

-85.56%

1.50B

-1.71%

-0.081

-67.75%

Estimates Revision

The market is revising Downward the revenue expectations for agilon health, inc. (AGL) for FY2025, with the revenue forecasts being adjusted by -10.5% over the past three months. During the same period, the stock price has changed by -14.66%.

Revenue Estimates for FY2025

Revise Downward

-10.5%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+4.25%

In Past 3 Month

Stock Price

Go Down

-14.66%

In Past 3 Month

18 Analyst Rating

44.11% Upside

Wall Street analysts forecast AGL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AGL is 4.28 USD with a low forecast of 2.00 USD and a high forecast of 8.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

11 Hold

2 Sell

Hold

44.11% Upside

Current: 2.970

Low

2.00

Averages

4.28

High

8.50

44.11% Upside

Current: 2.970

Low

2.00

Averages

4.28

High

8.50

Goldman Sachs

Jamie Perse

Hold

Maintains

$2.5 → $5

2025-05-08

New

Reason

Goldman Sachs

Jamie Perse

Price Target

$2.5 → $5

2025-05-08

New

Maintains

Hold

Reason

Barclays

Andrew Mok

Sell

Maintains

$2 → $3

2025-05-08

New

Reason

Barclays

Andrew Mok

Price Target

$2 → $3

2025-05-08

New

Maintains

Sell

Reason

JMP Securities

Constantine Davides

Hold

Reiterates

n/a

2025-04-28

Reason

JMP Securities

Constantine Davides

Price Target

n/a

2025-04-28

Reiterates

Hold

Reason

Citigroup

Daniel Grosslight

Hold

Strong Buy

Upgrades

$3.25 → $5

2025-04-25

Reason

Citigroup

Daniel Grosslight

Price Target

$3.25 → $5

2025-04-25

Upgrades

Hold

Strong Buy

Reason

Citi upgraded Agilon Health (AGL) to Buy from Neutral with a price target of $5, up from $3.25. The company has done an "admirable job" reducing risk in 2025 and should see accelerated margin improvement in 2026 and 2027 given the better than anticipated 2026 final rate notice, the analyst tells investors in a research note. The firm thinks the stock's 30% selloff post UnitedHealth (UNH) earnings is overdone as its recent conversation with Aledade co-Founder and CEO Farzad Mostashari gives it confidence that the magnitude of the company's issues are largely idiosyncratic to its Optum strategy. Agilon has a better field of vision to properly manage risk across plans when there is significant switching among the national insurers, contends Citi.

Baird

Michael Halloran

Hold

Maintains

$6 → $5

2025-04-15

Reason

Baird

Michael Halloran

Price Target

$6 → $5

2025-04-15

Maintains

Hold

Reason

Baird analyst Michael Ha downgraded Agilon Health to Neutral from Outperform with a price target of $5, down from $6. The firm sees minimal incremental buyers of stocks in the managed care and healthcare facilities group until the policy overhang clears. Baird does not not expect guidance raises as it believes companies will maintain 2025 "conservatism and cushion" given potential Part D and macro headwinds that may evolve later this year.

TD Cowen

Ryan Langston

Hold

Maintains

$3.5 → $6

2025-04-15

Reason

TD Cowen

Ryan Langston

Price Target

$3.5 → $6

2025-04-15

Maintains

Hold

Reason

TD Cowen analyst Gary Taylor raised the firm's price target on Agilon Health to $6 from $3.50 and keeps a Hold rating on the shares. The firm updated its model as part of its 1Q25 Healthcare Facilities and Managed Care preview. Their FY25/26 adjusted EBITDA estimates are largely unchanged, but they tweaked quarterly cadences.

See All Ratings

Valuation Metrics

The current forward P/E ratio for agilon health inc (AGL.N) is -9.71, compared to its 5-year average forward P/E of -30.56. For a more detailed relative valuation and DCF analysis to assess agilon health inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-30.56

Current PE

-9.71

Overvalued PE

276.80

Undervalued PE

-337.92

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

120.57

Current EV/EBITDA

-13.32

Overvalued EV/EBITDA

647.53

Undervalued EV/EBITDA

-406.39

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

2.19

Current PS

0.20

Overvalued PS

4.20

Undervalued PS

0.17